Last reviewed · How we verify
ZENTEL
Zentel, marketed by Chengdu Maternal and Children's Health Care Hospital, is an established therapeutic agent with a key composition patent expiring in 2028. Its primary strength lies in its specific mechanism of action, which targets a distinct biological pathway to achieve its therapeutic effect. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | ZENTEL |
|---|---|
| Also known as | albendazole |
| Sponsor | Chengdu Maternal and Children's Health Care Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (PHASE2)
- Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC (PHASE3)
- Co-administration of IVM and ALB in School-based Deworming in Uganda
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration (PHASE2,PHASE3)
- Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection (PHASE2)
- Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura (PHASE3)
- Efficacy and Safety of IVM/ALB Co-administration (PHASE2,PHASE3)
- Efficacy and Safety of MOX/ALB Co-administration (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZENTEL CI brief — competitive landscape report
- ZENTEL updates RSS · CI watch RSS
- Chengdu Maternal and Children's Health Care Hospital portfolio CI